2022, 2024
The risk for late-onset Alzheimer’s disease (AD) involves dozens of risk variants operating in diverse cell types. Elucidating the functions of these risk variants is critical to inform treatments but is challenging, in part because the vascular half of human brain cell types has eluded powerful single-cell assays. We will use our new vascular-capturing “VINE-seq” technique to comprehensively determine the cells and genes dysregulated by AD variants. We then will use chemical biology approaches to determine how identified AD variants dysregulate brain blood-brain barrier transport functions to compromise brain health and promote AD risk.
Andrew Yang, Ph.D.
